Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003655
Abstract: T cell-based immunotherapy, for example, with T cell-recruiting bispecific antibody (bsAb), has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions are still rare. Several tumor immune evasion mechanisms have… read more here.
Keywords: cell; recruiting bispecific; bsab; treatment ... See more keywords